Bexitrol F 25/250 HFA

Presentation:

• Each actuation delivers Salmeterol 25 mcg (as Salmeterol Xinafoate BP) and Fluticasone Propionate BP 250 mcg.
• Available as a pressurised inhalation, suspension in a pressurised container.  

Indications:

• Regular treatment of asthma where a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate for: 
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist.  
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist.  
• Treatment of chronic obstructive pulmonary disease (COPD).  

Dosage and Administration:

• For inhalation use only.
• Adults and adolescents 12 years and older: 2 puffs of Bexitrol F HFA 25/250 twice daily.
• Patients should be made aware that Bexitrol F HFA Inhaler must be used daily for optimum benefit, even when asymptomatic.  
• Patients should be regularly reassessed by a doctor, so that the strength of Bexitrol F HFA they are receiving remains optimal and is only changed on medical advice.  
• The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.  

Pharmacology:

• Bexitrol F HFA is a combination of Salmeterol and Fluticasone Propionate.
• Salmeterol is a selective, long-acting beta-2 agonist that relaxes the smooth muscles in the airways, leading to bronchodilation and improved airflow.
• Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. It exerts a topical anti-inflammatory effect in the lungs, reducing symptoms and exacerbations of asthma.

Side Effects:

• Common side effects may include headache, cold symptoms, oral thrush or oral sores, throat irritation, hoarseness, muscle pain, and joint pain.

Precautions:

• Use with caution in patients with pulmonary tuberculosis, severe cardiovascular disorders, heart rhythm abnormalities, diabetes mellitus, thyrotoxicosis, and hypokalaemia.
• Monitor the height of children on prolonged therapy.
• Do not stop therapy abruptly; treatment should be down-titrated.
• Advise patients to rinse their mouth out with water and spit out, and/or brush their teeth after each dose to minimise the risk of oropharyngeal candidiasis and hoarseness.  

Pregnancy & Lactation:

• Administration during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child.  

Storage:

• Protect from light and moisture by storing in a cool, dry place below 30°C.  
• Keep out of children's reach.

Therapeutic Class:

• Long-acting selective β-adrenoceptor stimulants.  
• Respiratory corticosteroids.

Important Note: This information is for general knowledge and informational purposes only and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.